Metagenics SPM Active Double Strength
Directions: Metagenics SPM Active
Adults: Take 1 capsule daily.
Clinical Benefits: Metagenics SPM Active
Specialised Pro-Resolving Mediators (SPMs)
SPM Active is a specific and targeted approach to facilitate the resolution phase in patients experiencing inflammation which may be failing to resolve in a timely manner. Unresolved inflammation can lead into low-grade, chronic inflammation that may worsen existing disease states, impair recovery and negatively affect healthy ageing.3 Chronic disease is an increasing health burden and it is now estimated that 1 in 3 Australians live with at least one chronic inflammatory condition including arthritis and other musculoskeletal disorders, cardiovascular disease and diabetes mellitus.4 These health issues are characterised by inflammatory processes disrupting healing and driving chronic states indicating the need for SPMs to help support healthy resolution outcomes.
SPMs found in SPM Active are lipid mediators that occur naturally in the body and have been found in various human tissue (such as the brain, lymph nodes and synovial fluid).5 SPMs orchestrate resolution at the site of inflammation to assist tissue repair, healing, recovery and the return to homeostasis.6 These mediators help to:
- Activate the resolution phase.
- Signal to, and recruit certain immune cells and inflammatory mediators.
- Repair damage and clearance of pathogens.
- Prevent further pathological inflammation without immunosuppression.7,8
Despite omega-3 EPA and DHA being precursors of SPMs, they do not possess significant pro-resolving properties.9 Metagenics, in collaboration with SPMs experts and world-renowned leaders in the field of resolution physiology, are the first to set the standard for defining SPMs within a therapeutic supplement. Using a refined, patent pending fractionation process, specific SPM fractions are standardised for consistent dosing and therapeutic patient outcomes. The special fraction and ratio is isolated, concentrated and measured for bioactivity to verify the active SPMs 17-HDHA and 18-HEPE. This process is exclusive to Metagenics, providing an inflammation-specific solution.
Liponva SPM's is a trademark of SOLUTEX GC.
Patients:
Australia/AU 2013259503
New Zealand/NZ 702325
Ingredients: Metagenics SPM Active
Each Metagenics SPM Active capsule contains: | |
Concentrated fish Omega-3 triglycerides (LIPINOVA-11TGTM) | 996mg |
Equivalent Eicosapentaenoic acid (EPA) | 100mg |
Equivalent Docosahexaenoic acid (DHA) | 201mg |
Contains active SPMs 17-HDHA and 18-HEPE
Metagenics SPM Active is free from corn, dairy protein, lactose, eggs, gluten, wheat, nuts, yeast, soy protein and starches.
Metagenics SPM Active is free from artificial colours, sweeteners and flavours.
Cautions and Contraindications: Metagenics SPM Active
Contraindications
- Allergies and Sensitivities: Avoid in people allergic to fish. Although fish oil is highly purified, those with extreme fish allergy (anaphylaxis) would be advised to avoid it.82
Moderate Level Cautions
- Anticoagulant/antiplatelet drugs: Clinical trials have shown high-dose fish oil omega-3 fatty acid consumption to be safe, even when concurrently administered with other agents that may increase bleeding (i.e. antiplatelet or antithrombotic medications such as aspirin and warfarin). The clinical trial evidence suggests that if such an increased bleeding risk exists, the risk is very small and not of clinical significance. For example, 6.8 g of EPA/DHA daily for 6 months showed no adverse effects. However, it is reasonable to monitor patients treated with fish oils and anticoagulants for international normalised ratio (INR) as well as potential adverse bleeding experiences.83,84
- Bleeding disorders: Due to the anticoagulant properties of fish oils, there have been safety concerns in regards to the risk of increased bleeding tendency and postoperative bleeding. Although this theoretical possibility is not reflected functionally in human studies, it would still warrant caution in situations which carry a high risk of bleeding such as haemorrhagic stroke and postoperative events. To minimise the risk of exacerbation of these bleeding events it is recommended to discontinue use of fish oils during acute bleeding episodes, such as during and immediately after a haemorrhagic stroke, or in patients who are at high risk for haemorrhagic stroke.85,86
- Surgery: Due to the anticoagulant properties of fish oils, there have been safety concerns in regards to the risk of increased bleeding tendency and postoperative bleeding. Although this theoretical possibility is not reflected functionally in human studies, it would still warrant caution in situations which carry a high risk of bleeding such as haemorrhagic stroke and postoperative events. To minimise the risk of exacerbation of these bleeding events it is recommended to discontinue use of fish oils 4-7 days before elective procedures which have a high risk for bleeding complications. However, consider fish oil supplementation postoperatively if there are no bleeding complications, given that supplementation may reduce the risk of thrombotic and cardiovascular events which could occur following major surgery.87,88
Low Level Cautions
- None of note.
Pregnancy and Breastfeeding: Metagenics SPM Active
- Safe to use in pregnancy and breastfeeding
Storage: Metagenics SPM Active
Store below 30°C
References: Metagenics SPM Active
82 Fish Oil. In: Natural Medicines Comprehensive Database [database on the Internet]. Stockton (CA): Therapeutic Research Faculty; 1995-2008 [cited 2017 Feb 21]. Available from: http://www.naturaldatabase.com. subscription required to view.
83 Bays HE. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol. 2007;99(6 Suppl 1):35C-43C.
84 Harris WS. Expert opinion: omega-3 fatty acids and bleeding – cause for concern? Am J Cardiol. 2007;99(6 Suppl 1):44C-46C.
85 Bays HE. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol. 2007;99(6 Suppl 1):35C-43C.
86 Harris WS. Expert opinion: omega-3 fatty acids and bleeding – cause for concern? Am J Cardiol. 2007;99(6 Suppl 1):44C-46C.
87 Bays HE. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol. 2007;99(6 Suppl 1):35C-43C.
88 Harris WS. Expert opinion: omega-3 fatty acids and bleeding – cause for concern? Am J Cardiol 2007;99(6 Suppl 1):44C-46C.
89 Fish Oil. In: Natural Medicines Comprehensive Database [database on the Internet]. Stockton (CA): Therapeutic Research Faculty; 1995-2008 [cited 2017 Feb 21]. Available from: http://www.naturaldatabase.com. subscription required to view.